Emerging Therapy for Adrenocortical Carcinoma

References

• De Reynies A , AssieG, RickmanDSet al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol.27(7), 1108–1115 (2009).
   PubMed Web of Science ®Google Scholar
• Allolio B , FassnachtM. Clinical review: Adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab.91(6), 2027–2037 (2006).
   PubMed Web of Science ®Google Scholar
• Luton JP , CerdasS, BillaudLet al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N. Engl. J. Med.322(17), 1195–1201 (1990).
   PubMed Web of Science ®Google Scholar
• Fassnacht M , KroissM, AllolioB. Update in adrenocortical carcinoma. J. Clin. Endocrinol. Metab.98(12), 4551–4564 (2013).
   PubMed Web of Science ®Google Scholar
• Fassnacht M , JohanssenS, QuinklerMet al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer115(2), 243–250 (2009).
   PubMed Web of Science ®Google Scholar
• Schulick RD , BrennanMF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann. Surg. Oncol.6(8), 719–726 (1999).
   PubMed Web of Science ®Google Scholar
• Fassnacht M , JohanssenS, FenskeWet al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J. Clin. Endocrinol. Metab.95(11), 4925–4932 (2010).
   PubMed Web of Science ®Google Scholar
• Erdogan I , DeutschbeinT, JurowichCet al. The role of surgery in the management of recurrent adrenocortical carcinoma. J. Clin. Endocrinol. Metab.98(1), 181–191 (2013).
   PubMed Web of Science ®Google Scholar
• Datrice NM , LanganRC, RipleyRTet al. Operative management for recurrent and metastatic adrenocortical carcinoma. J. Surg. Oncol.105(7), 709–713 (2012).
   PubMed Web of Science ®Google Scholar
• Gaujoux S , Al-AhmadieH, AllenPJet al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann. Surg. Oncol. 19(8), 2643–2651 (2012).
   PubMed Web of Science ®Google Scholar
• Op Den Winkel J , PfannschmidtJ, MuleyTet al. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. Ann. Thorac. Surg.92(6), 1965–1970 (2011).
   PubMed Web of Science ®Google Scholar
• Kemp CD , RipleyRT, MathurAet al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann. Thorac. Surg.92(4), 1195–1200 (2011).
   PubMed Web of Science ®Google Scholar
• Berruti A , TerzoloM, SperonePet al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr. Relat. Cancer12(3), 657–666 (2005).
   PubMed Web of Science ®Google Scholar
• Haak HR , HermansJ, Van De VeldeCJet al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br. J. Cancer69(5), 947–951 (1994).
   PubMed Web of Science ®Google Scholar
• Baudin E , PellegritiG, BonnayMet al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer92(6), 1385–1392 (2001).
   PubMed Web of Science ®Google Scholar
• Gonzalez RJ , TammEP, NgCet al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery142(6), 867–875; discussion 867–875 (2007).
   PubMed Web of Science ®Google Scholar
• Kerkhofs TM , BaudinE, TerzoloMet al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab.98(12), 4759–4767 (2013).
   PubMed Web of Science ®Google Scholar
• Khan TS , ImamH, JuhlinCet al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann. Oncol.11(10), 1281–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Fassnacht M , TerzoloM, AllolioBet al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med.366(23), 2189–2197 (2012).
   PubMed Web of Science ®Google Scholar
• Terzolo M , AngeliA, FassnachtMet al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med.356(23), 2372–2380 (2007).
   PubMed Web of Science ®Google Scholar
• Grubbs EG , CallenderGG, XingYet al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann. Surg. Oncol.17(1), 263–270 (2010).
   PubMed Web of Science ®Google Scholar
• Wangberg B , Khorram-ManeshA, JanssonSet al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr. Relat. Cancer17(1), 265–272 (2010).
   PubMed Web of Science ®Google Scholar
• Else T , WilliamsAR, SabolchA, JollyS, MillerBS, HammerGD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab.99(2), 455–461 (2014).
   PubMed Web of Science ®Google Scholar
• Abiven G , CosteJ, GroussinLet al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J. Clin. Endocrinol. Metab.91(7), 2650–2655 (2006).
   PubMed Web of Science ®Google Scholar
• Bertherat J , CosteJ, BertagnaX. Adjuvant mitotane in adrenocortical carcinoma. N. Engl. J. Med.357(12), 1256–1257; author reply 1259 (2007).
   PubMed Web of Science ®Google Scholar
• Terzolo M , ArditoA, ZaggiaBet al. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine42(3), 521–525 (2012).
   PubMed Web of Science ®Google Scholar
• Assie G , JouinotA, BertheratJ. The ‘omics’ of adrenocortical tumours for personalized medicine. Nat. Rev. Endocrinol.10(4), 215–228 (2014).
   PubMed Web of Science ®Google Scholar
• Gicquel C , BertagnaX, Le BoucY. Recent advances in the pathogenesis of adrenocortical tumours. Eur. J. Endocrinol.133(2), 133–144 (1995).
   PubMed Web of Science ®Google Scholar
• Gicquel C , BertagnaX, GastonVet al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res.61(18), 6762–6767 (2001).
   PubMed Web of Science ®Google Scholar
• De Martino MC , Al GhuzlanA, AubertSet al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J. Clin. Endocrinol. Metab.98(10), 4080–4088 (2013).
   PubMed Web of Science ®Google Scholar
• Velazquez-Fernandez D , LaurellC, GeliJet al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery138(6), 1087–1094 (2005).
   PubMed Web of Science ®Google Scholar
• Giordano TJ , KuickR, ElseTet al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res.15(2), 668–676 (2009).
   PubMed Web of Science ®Google Scholar
• Ragazzon B , LibeR, AssieGet al. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. Eur. J. Endocrinol.170(3), 385–391 (2014).
   PubMed Web of Science ®Google Scholar
• Chabre O , LibeR, AssieGet al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr. Relat. Cancer20(4), 579–594 (2013).
   PubMed Web of Science ®Google Scholar
• Patterson EE , HollowayAK, WengJ, FojoT, KebebewE. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer117(8), 1630–1639 (2011).
   PubMed Web of Science ®Google Scholar
• Soon PS , TaconLJ, GillAJet al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin. Cancer Res.15(24), 7684–7692 (2009).
   PubMed Web of Science ®Google Scholar
• Giordano TJ , ThomasDG, KuickRet al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol.162(2), 521–531 (2003).
   PubMed Web of Science ®Google Scholar
• Slater EP , DiehlSM, LangerPet al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur. J. Endocrinol.154(4), 587–598 (2006).
   PubMed Web of Science ®Google Scholar
• Ozata DM , CaramutaS, Velazquez-FernandezDet al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr. Relat. Cancer18(6), 643–655 (2011).
   PubMed Web of Science ®Google Scholar
• Tombol Z , SzaboPM, MolnarVet al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr. Relat. Cancer16(3), 895–906 (2009).
   PubMed Web of Science ®Google Scholar
• West AN , NealeGA, PoundsSet al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res.67(2), 600–608 (2007).
   PubMed Web of Science ®Google Scholar
• Weber MM , AuernhammerCJ, KiessW, EngelhardtD. Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur. J. Endocrinol.136(3), 296–303 (1997).
   PubMed Web of Science ®Google Scholar
• Barlaskar FM , SpaldingAC, HeatonJHet al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab.94(1), 204–212 (2009).
   PubMed Web of Science ®Google Scholar
• Haluska P , WordenF, OlmosDet al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother. Pharmacol.65(4), 765–773 (2010).
   PubMed Web of Science ®Google Scholar
• Liu P , ChengH, RobertsTM, ZhaoJJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov.8(8), 627–644 (2009).
   PubMed Web of Science ®Google Scholar
• Hay N , SonenbergN. Upstream and downstream of mTOR. Genes Dev.18(16), 1926–1945 (2004).
   PubMed Web of Science ®Google Scholar
• Doghman M , El WakilA, CardinaudBet al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res.70(11), 4666–4675 (2010).
   PubMed Web of Science ®Google Scholar
• Wan X , HarkavyB, ShenN, GroharP, HelmanLJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene26(13), 1932–1940 (2007).
   PubMed Web of Science ®Google Scholar
• O’Reilly KE , RojoF, SheQBet al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.66(3), 1500–1508 (2006).
   PubMed Web of Science ®Google Scholar
• Kurmasheva RT , DudkinL, BillupsC, DebelenkoLV, MortonCL, HoughtonPJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res.69(19), 7662–7671 (2009).
   PubMed Web of Science ®Google Scholar
• Naing A , KurzrockR, BurgerAet al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin. Cancer Res.17(18), 6052–6060 (2011).
   PubMed Web of Science ®Google Scholar
• Naing A , LorussoP, FuSet al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br. J. Cancer108(4), 826–830 (2013).
   PubMed Web of Science ®Google Scholar
• Ganesan P , Piha-PaulS, NaingAet al. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest. New Drugs31(6), 1505–1513 (2013).
   PubMed Web of Science ®Google Scholar
• Kamio T , ShigematsuK, SouH, KawaiK, TsuchiyamaH. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum. Pathol.21(3), 277–282 (1990).
   PubMed Web of Science ®Google Scholar
• Sasano H , SuzukiT, ShizawaS, KatoK, NaguraH. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod. Pathol.7(7), 741–746 (1994).
   PubMed Web of Science ®Google Scholar
• Nakamura M , MikiY, AkahiraJet al. An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocr. Pathol.20(1), 17–23 (2009).
   PubMed Web of Science ®Google Scholar
• Adam P , HahnerS, HartmannMet al. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod. Pathol.23(12), 1596–1604 (2010).
   PubMed Web of Science ®Google Scholar
• De Fraipont F , El AtifiM, GicquelC, BertagnaX, ChambazEM, FeigeJJ. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab.85(12), 4734–4741 (2000).
   PubMed Web of Science ®Google Scholar
• Bernini GP , MorettiA, BonadioAGet al. Angiogenesis in human normal and pathologic adrenal cortex. J. Clin. Endocrinol. Metab.87(11), 4961–4965 (2002).
   PubMed Web of Science ®Google Scholar
• Samnotra V , Vassilopoulou-SellinR, FojoATet al. A Phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma. J. Clin. Oncol.25(18 Suppl.), 15527 (2007).
   Web of Science ®Google Scholar
• Quinkler M , HahnerS, WortmannSet al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J. Clin. Endocrinol. Metab.93(6), 2057–2062 (2008).
   PubMed Web of Science ®Google Scholar
• Wortmann S , QuinklerM, RitterCet al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur. J. Endocrinol.162(2), 349–356 (2010).
   PubMed Web of Science ®Google Scholar
• Hong DS , SebtiSM, NewmanRAet al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin. Cancer Res.15(22), 7061–7068 (2009).
   PubMed Web of Science ®Google Scholar
• Butler C , ButlerWM, RizviAA. Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr. Pract.16(3), 441–445 (2010).
   PubMed Web of Science ®Google Scholar
• Berruti A , SperoneP, FerreroAet al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur. J. Endocrinol.166(3), 451–458 (2012).
   PubMed Web of Science ®Google Scholar
• Lee JO , LeeKW, KimCJet al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J. Clin. Oncol.39(3), 183–185 (2009).
   PubMed Web of Science ®Google Scholar
• Kroiss M , QuinklerM, JohanssenSet al. Sunitinib in refractory adrenocortical carcinoma: a Phase II, single-arm, open-label trial. J. Clin. Endocrinol. Metab.97(10), 3495–3503 (2012).
   PubMed Web of Science ®Google Scholar
• Kroiss M , QuinklerM, LutzWK, AllolioB, FassnachtM. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin. Endocrinol.75(5), 585–591 (2011).
   PubMed Web of Science ®Google Scholar
• Chortis V , TaylorAE, SchneiderPet al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J. Clin. Endocrinol. Metab.98(1), 161–171 (2013).
   PubMed Web of Science ®Google Scholar
• Assie G , GiordanoTJ, BertheratJ. Gene expression profiling in adrenocortical neoplasia. Mol. Cell. Endocrinol.351(1), 111–117 (2012).
   PubMed Web of Science ®Google Scholar
• Ragazzon B , AssieG, BertheratJ. Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr. Relat. Cancer18(2), R15–R27 (2011).
   PubMed Web of Science ®Google Scholar
• Tissier F , CavardC, GroussinLet al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res.65(17), 7622–7627 (2005).
   PubMed Web of Science ®Google Scholar
• Kim AC , BarlaskarFM, HeatonJHet al. In search of adrenocortical stem and progenitor cells. Endocr. Rev.30(3), 241–263 (2009).
   PubMed Web of Science ®Google Scholar
• Gaujoux S , GrabarS, FassnachtMet al. Beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin. Cancer Res.17(2), 328–336 (2011).
   PubMed Web of Science ®Google Scholar
• Berthon A , Sahut-BarnolaI, Lambert-LanglaisSet al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum. Mol. Genet.19(8), 1561–1576 (2010).
   PubMed Web of Science ®Google Scholar
• Doghman M , CazarethJ, LalliE. The T cell factor/beta-catenin antagonist PKF115–584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab.93(8), 3222–3225 (2008).
   PubMed Web of Science ®Google Scholar
• Doghman M , CazarethJ, DouguetD, MadouxF, HodderP, LalliE. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. J. Clin. Endocrinol. Metab.94(6), 2178–2183 (2009).
   PubMed Web of Science ®Google Scholar
• Pianovski MA , CavalliLR, FigueiredoBCet al. SF-1 overexpression in childhood adrenocortical tumours. Eur. J. Cancer42(8), 1040–1043 (2006).
   PubMed Web of Science ®Google Scholar
• Doghman M , KarpovaT, RodriguesGAet al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol. Endocrinol.21(12), 2968–2987 (2007).
   PubMedGoogle Scholar
• Sbiera S , SchmullS, AssieGet al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J. Clin. Endocrinol. Metab.95(10), E161–E171 (2010).
   PubMed Web of Science ®Google Scholar
• Betz MJ , ShapiroI, FassnachtM, HahnerS, ReinckeM, BeuschleinF. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J. Clin. Endocrinol. Metab.90(7), 3886–3896 (2005).
   PubMed Web of Science ®Google Scholar
• Ferruzzi P , CeniE, TarocchiMet al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J. Clin. Endocrinol. Metab.90(3), 1332–1339 (2005).
   PubMed Web of Science ®Google Scholar
• Blanquicett C , RomanJ, HartCM. Thiazolidinediones as anti-cancer agents. Cancer Ther.6(A), 25–34 (2008).
   PubMedGoogle Scholar
• Cantini G , LombardiA, PiscitelliEet al. Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Res.2008, 904041 (2008).
   PubMed Web of Science ®Google Scholar
• Cerquetti L , SampaoliC, AmendolaDet al. Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Exp. Cell Res.317(10), 1397–1410 (2011).
   PubMed Web of Science ®Google Scholar
• Luconi M , MangoniM, GelminiSet al. Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr. Relat. Cancer17(1), 169–177 (2010).
   PubMed Web of Science ®Google Scholar
• Barzon L , MasiG, PacentiMet al. Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Arch.452(2), 181–191 (2008).
   PubMed Web of Science ®Google Scholar
• Montanaro D , MaggioliniM, RecchiaAGet al. Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation. J. Mol. Endocrinol.35(2), 245–256 (2005).
   PubMed Web of Science ®Google Scholar
• Sirianni R , ZoleaF, ChimentoAet al. Targeting estrogen receptor-alpha reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. J. Clin. Endocrinol. Metab.97(12), E2238–E2250 (2012).
   PubMed Web of Science ®Google Scholar
• Eelen G , GysemansC, VerlindenLet al. Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logs. Curr. Med. Chem.14(17), 1893–1910 (2007).
   PubMed Web of Science ®Google Scholar
• Yang L , MaJ, ZhangX, FanY, WangL. Protective role of the vitamin D receptor. Cell. Immunol.279(2), 160–166 (2012).
   PubMed Web of Science ®Google Scholar
• Hossein-Nezhad A , SpiraA, HolickMF. Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS ONE8(3), e58725 (2013).
   PubMed Web of Science ®Google Scholar
• Pilon C , UrbanetR, WilliamsTAet al. 1alpha,25-dihydroxyvitamin D3 inhibits the human H295R cell proliferation by cell cycle arrest: a model for a protective role of vitamin D receptor against adrenocortical cancer. J. Steroid Biochem. Mol. Biol.140, 26–33 (2014).
   PubMed Web of Science ®Google Scholar